| MeSH term | MeSH ID | Detail |
|---|---|---|
| Body Weight | D001835 | 333 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Seizures | D012640 | 87 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Atherosclerosis | D050197 | 85 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Albano L et al. | OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. | 2013 | Transplantation | pmid:23982340 |
| Sheiner PA et al. | Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506. | 1994 | Transplantation | pmid:7513099 |
| Troppmann C et al. | Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. | 2003 | Transplantation | pmid:12883205 |
| Therapondos G et al. | Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? | 2003 | Transplantation | pmid:12883220 |
| Fredericks S et al. | Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. | 2006 | Transplantation | pmid:16969296 |
| Ogunseinde BA et al. | A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. | 2003 | Transplantation | pmid:12883222 |
| Keenan RJ et al. | Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. | 1991 | Transplantation | pmid:1719668 |
| Thomas J et al. | The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. | 1990 | Transplantation | pmid:1689518 |
| Marcos A et al. | Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. | 2004 | Transplantation | pmid:15480160 |
| Vathsala A et al. | Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. | 1990 | Transplantation | pmid:1689520 |
| Gralla J and Wiseman AC | Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. | 2009 | Transplantation | pmid:19502965 |
| Alloway RR | Mounting Clinical Evidence With Tacrolimus Generic Products. | 2017 | Transplantation | pmid:28749820 |
| Ellis D et al. | Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10532541 |
| Migita K et al. | FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. | 1999 | Transplantation | pmid:10532544 |
| Leroy-Matheron C et al. | Inhibitor against coagulation factor V after liver transplantation. | 1999 | Transplantation | pmid:10532550 |
| Lee D et al. | Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. | 2017 | Transplantation | pmid:27779572 |
| Boleslawski E et al. | Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. | 2004 | Transplantation | pmid:15223897 |
| Wozniak LJ et al. | Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. | 2015 | Transplantation | pmid:26038872 |
| Hostettler KE et al. | Cyclosporine A mediates fibroproliferation through epithelial cells. | 2004 | Transplantation | pmid:15223908 |
| Boldt A et al. | The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. | 2006 | Transplantation | pmid:16906043 |
| Yang CW et al. | Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. | 2003 | Transplantation | pmid:12544865 |
| Kuypers DR et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. | 2010 | Transplantation | pmid:20555228 |
| Lykavieris P et al. | Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. | 2003 | Transplantation | pmid:12544888 |
| Narayanan M et al. | Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. | 2013 | Transplantation | pmid:23423268 |
| Gaber AO et al. | Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. | 2013 | Transplantation | pmid:23423269 |
| Molano RD et al. | Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody. | 2003 | Transplantation | pmid:12811239 |
| Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
| Bilolo KK et al. | Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. | 2003 | Transplantation | pmid:12811249 |
| Miyakoshi S et al. | Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. | 2007 | Transplantation | pmid:17700155 |
| Naesens M et al. | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. | 2007 | Transplantation | pmid:17700162 |
| Waldman WJ et al. | Inhibition of angiogenesis-related endothelial activity by the experimental immunosuppressive agent leflunomide. | 2001 | Transplantation | pmid:11707749 |
| Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
| Kato T et al. | Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. | 2007 | Transplantation | pmid:17984834 |
| Jain A et al. | Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. | 2014 | Transplantation | pmid:25285953 |
| Morrissey PE et al. | Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. | 1997 | Transplantation | pmid:9089224 |
| Woodle ES et al. | FK506--reversal of humorally mediated cardiac allograft rejection in the presence of preformed anti-class I antibody. | 1993 | Transplantation | pmid:7504346 |
| Kiuchi T et al. | A hepatic graft tuberculosis transmitted from a living-related donor. | 1997 | Transplantation | pmid:9089234 |
| Jindal RM et al. | Effect of deoxyspergualin on the endocrine function of the rat pancreas. | 1993 | Transplantation | pmid:7504347 |
| Jeske HC et al. | Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat. | 2003 | Transplantation | pmid:14557751 |
| Millis JM et al. | Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. | 1996 | Transplantation | pmid:8629298 |
| Muthukumar T et al. | HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. | 2013 | Transplantation | pmid:23503504 |
| Hricik DE et al. | Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. | 2007 | Transplantation | pmid:17297401 |
| Sheiner PA et al. | Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction. | 1997 | Transplantation | pmid:9355846 |
| Karlsson H and Nässberger L | FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. | 1997 | Transplantation | pmid:9355847 |
| Reding R et al. | Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children. | 1994 | Transplantation | pmid:7507272 |
| Kitayama T et al. | Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. | 2003 | Transplantation | pmid:12605126 |
| Storb R et al. | FK-506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated dog leukocyte antigen-nonidentical donors. | 1993 | Transplantation | pmid:7692635 |
| Egidi MF and Gaber AO | Outcomes of African-American kidney-transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. | 2003 | Transplantation | pmid:12605133 |
| Thervet E et al. | Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. | 2003 | Transplantation | pmid:14578760 |
| McDiarmid SV et al. | A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. | 1993 | Transplantation | pmid:7692636 |
| Osowski CL et al. | Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. | 1996 | Transplantation | pmid:8610430 |
| Tabasco-Minguillan J et al. | Insulin requirements after liver transplantation and FK-506 immunosuppression. | 1993 | Transplantation | pmid:7692637 |
| Jain A et al. | Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. | 2000 | Transplantation | pmid:10972220 |
| Wang SC et al. | A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. | 1993 | Transplantation | pmid:7692640 |
| Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. | 2011 | Transplantation | pmid:21107305 |
| Textor SC et al. | Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. | 1993 | Transplantation | pmid:7685934 |
| Jurcevic S et al. | A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. | 1998 | Transplantation | pmid:9603168 |
| Borrows R et al. | Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. | 2006 | Transplantation | pmid:16421488 |
| Kung L and Halloran PF | Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. | 2000 | Transplantation | pmid:10933159 |
| Beatty PR et al. | Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. | 1998 | Transplantation | pmid:9603175 |
| Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
| Maes BD et al. | Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. | 1999 | Transplantation | pmid:10589943 |
| Gruber SA et al. | Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. | 2000 | Transplantation | pmid:10933170 |
| Shapiro R et al. | Alopecia as a consequence of tacrolimus therapy. | 1998 | Transplantation | pmid:9603186 |
| Shapiro AM et al. | Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. | 2002 | Transplantation | pmid:12490784 |
| Fernandez LA et al. | The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. | 1999 | Transplantation | pmid:10589951 |
| Lang T et al. | Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. | 1996 | Transplantation | pmid:8824477 |
| Mehra MR et al. | Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. | 2002 | Transplantation | pmid:12490790 |
| Kandula P et al. | Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. | 2012 | Transplantation | pmid:23037007 |
| First MR et al. | New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. | 2013 | Transplantation | pmid:23619735 |
| Naesens M et al. | Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. | 2008 | Transplantation | pmid:18431234 |
| Dean PG et al. | Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. | 2008 | Transplantation | pmid:18431244 |
| Shoji T et al. | Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. | 2007 | Transplantation | pmid:18091523 |
| Curran CF et al. | Acute overdoses of tacrolimus. | 1996 | Transplantation | pmid:8932293 |
| Reyes J et al. | Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. | 2000 | Transplantation | pmid:10910279 |
| Taylor-Fishwick DA et al. | Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. | 1993 | Transplantation | pmid:7689258 |
| Cantarovich D et al. | Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. | 2005 | Transplantation | pmid:15714172 |
| Yamauchi A et al. | Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. | 2002 | Transplantation | pmid:12352921 |
| Nguyen L et al. | Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. | 2012 | Transplantation | pmid:22960763 |
| Vafadari R et al. | Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. | 2012 | Transplantation | pmid:22960764 |
| Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
| Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
| Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
| Radkowski M et al. | Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. | 1998 | Transplantation | pmid:9753352 |
| Nankivell BJ et al. | Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. | 2004 | Transplantation | pmid:15167607 |
| Ciancio G et al. | A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. | 2013 | Transplantation | pmid:23903014 |
| Warty V et al. | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes. | 1988 | Transplantation | pmid:2458643 |
| Kuypers DR et al. | Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. | 2013 | Transplantation | pmid:23263559 |
| Hewitt CW and Black KS | Comparative studies of FK506 with cyclosporine. | 1988 | Transplantation | pmid:2458644 |
| Ellis D et al. | Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. | 1991 | Transplantation | pmid:1714643 |
| Lerut J et al. | Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. | 2005 | Transplantation | pmid:16314784 |
| White M et al. | Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. | 2006 | Transplantation | pmid:17006323 |
| Wissing KM et al. | Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. | 2006 | Transplantation | pmid:17006324 |
| Gruessner RW et al. | Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. | 2008 | Transplantation | pmid:18192910 |
| Komori K et al. | The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. | 2008 | Transplantation | pmid:18192920 |
| Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
| Rezeig MA et al. | Kaposi's sarcoma in liver transplant recipients on FK506: two case reports. | 1997 | Transplantation | pmid:9175820 |
| Foster RD et al. | Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. | 2003 | Transplantation | pmid:14508367 |
| Talento A et al. | A single administration of LFA-1 antibody confers prolonged allograft survival. | 1993 | Transplantation | pmid:7679531 |
| Mor E et al. | Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7513098 |